Nationwide Children’s Hospital in Columbus is creating Andelyn Biosciences, a new for-profit subsidiary, to manufacture gene therapy products for the biotechnology and pharmaceutical industries.
The field of gene therapy has been around for about two decades and can provide cures for diseases that never had one before, said Dr. Dennis Durbin, chief scientific officer for the Abigail Wexner Research Institute at Nationwide Children’s.
Durbin has seen numerous breakthroughs in gene therapies over the past decade and said the U.S. Food and Drug Administration estimates it will start approving five to 10 new cell and gene therapies each year over the next couple of years.
Click here to read the complete article.
Story excerpt provided by The Columbus Dispatch. See related article in Columbus Business First.
Written by Megan Henry.
Originally published January 13, 2020.